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Abstract
Prior genome-wide association studies for oral clefts have focused on clinic-based samples with 
unclear generalizability. Prior samples were also small for investigating effects by cleft type and 
exclusively studied isolated clefts (those occurring without other birth defects). We estimated the 
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effects of 17 top loci on cleft types in both isolated and nonisolated cases in the largest consortium 
to date of European-descent population-based studies. Our analytic approach focused on a mother-
child dyad case-control design, but it also allowed analyzing mother-only or child-only genotypes 
to maximize power. Our total sample included 1,875 cases with isolated clefts, 459 cases with 
nonisolated clefts, and 3,749 controls. After correcting for multiple testing, we observed 
significant associations between fetal single-nucleotide polymorphisms (SNPs) at IRF6, PAX7, 
8q21.3, 8q24, KIAA1598-VAX1, and MAFB and isolated cleft lip only (CLO) and cleft lip and 
palate (CLP). Significant associations were observed between isolated CLO and fetal SNPs near 
TPM1 and NOG1 and between CLP and fetal SNPs at ABCA4-ARHGAP29, THADA, FOXE1, 
and SPRY2. Overall, effects were similar for isolated CLO and CLP, except for ABCA4-
ARHGAP29. A protective effect was observed for the fetal NOG1 SNP on cleft palate only, 
opposite in direction to the effect on CLO. For most fetal SNPs, a dose-response allelic effect was 
observed. No evidence of parent-of-origin or maternal genome effects was observed. Overall, 
effect direction and magnitude were similar between isolated and nonisolated clefts, suggesting 
that several loci are modifiers of cleft risk in both isolated and nonisolated forms. Our results 
provide reliable estimates of the effects of top loci on risks of oral clefts in a population of 
European descent.
Keywords
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Introduction
Genome-wide association studies (GWASs) of isolated cleft lip with or without cleft palate 
(CL/P) occurring without other birth defects have identified multiple loci with evidence of 
etiologic mutations (Birnbaum et al. 2009; Grant et al. 2009; Beaty et al. 2010; Beaty et al. 
2013; Mangold et al. 2010; Camargo et al. 2012; Ludwig et al., 2012; Sun et al. 2015; Wolf 
et al. 2015). Key loci include (in genomic order) PAX7 (1p36), ABCA4-ARHGAP29 
(1p22.1), IRF6 (1q32), THADA (2p21), DCAF4L2 (8q21.3), 8q24, GADD45G (9q22.1), 
KIAA1598-VAX1 (10q25.3), SPRY2 (13q31.3), TPM1 (15q22.2), NTN1 (17p13.1), NOG1 
(17q22), and MAFB (20q12). More recent and larger GWASs have found evidence for these 
loci and additional ones such as FOXE1 (9q22.3; Leslie, Carlson, et al. 2016; Leslie et al. 
2017; Yu et al. 2017). Candidate gene studies first suggested some of these genes/loci for 
CL/P, such as IRF6 and FOXE1, but also others, such as MSX1, FGFR2, and CRISPLD2 
(Chiquet et al. 2007; Leslie and Marazita 2013). Interestingly, except perhaps for FOXE1 
(Moreno et al. 2009; Leslie et al. 2017), there is little evidence that the loci for CL/P are 
related to cleft palate only (CPO) especially at GWAS significance levels.
Despite the convincing evidence for many loci, there are several limitations in prior 
assessments of their effects. Previous studies have almost exclusively focused on clinic-
based rather than population-based samples. Genetic risk estimates from clinic-based 
samples may have limited generalizability because of potential ascertainment bias (Kukull 
and Ganguli 2012). In contrast, population-based samples provide more reliable and 
generalizable estimates for quantifying the epidemiologic and clinical relevance of these top 
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loci. Prior studies have had modest sample sizes that may lack power to accurately estimate 
separate effects on cleft lip only (CLO) versus cleft lip with palate (CLP) and meaningfully 
examine potential differences between these 2 phenotypes, and most examined CL/P as 1 
phenotype. Small sample sizes have been a challenge for examining genetic effects on CPO, 
a less common trait with a higher proportion of syndromic cases. Another limitation is 
focusing on fetal gene effects with little attention to additional underlying genetic 
mechanisms, such as maternal gene (MG) and parent-of-origin (PoO) effects. MG effects 
influence fetal intra-uterine environment conditional on fetal genes. PoO effects indicate 
differential effects in fetal genes depending on whether they were inherited from the mother 
or the father. Two studies of MG and PoO effects based on GWAS data (Shi et al. 2012; 
Garg et al. 2014) found nonsignificant effects. However, their study samples were relatively 
modest for a meaningful assessment of such effects. Finally, GWASs have focused on 
isolated orofacial clefting (OFC), and little is known about whether these loci are relevant 
for nonisolated OFC occurring with other birth defects or syndromes.
In this study, we estimated the effects of the main OFC loci in GWASs and top candidate 
gene studies published before February 2016 on risks of isolated CLO, CLP, and CPO 
examined as separate phenotypes in the largest consortium to date of population-based 
samples of European descent. We examined fetal, MG, and PoO effects, and we estimated 
effects on non-isolated OFC separately for CL/P and CPO. We used individual-level data 
pooled across 5 population-based samples, accounting for study differences through 
stratified estimation, to study a total of 31 single-nucleotide polymorphisms (SNPs) within 
17 genes/loci (Appendix Table 1). Our work provides the most definitive assessment to date 
of the importance of these loci for each of the 3 isolated OFC phenotypes in populations of 
European descent, including risk estimates that may be meaningful for clinical counseling 
and etiologic research. Furthermore, we provide novel evidence on the relevance of these 
loci for nonisolated OFC.
Methods
Our study employs data from a unique international consortium of 5 OFC population-based 
case-control studies: the Norway Facial Clefts Study, the Norwegian Mother and Child 
Cohort, the Utah Child and Family Health Study, the Iowa Case-Control Study, and the US 
National Birth Defects Prevention Study. Cases and controls for each study were identified 
through national or state-based registries that provide population-based surveillance of OFC. 
Mothers and children were enrolled and provided DNA specimens. The controls across all 
studies included children without oral clefts or other major birth defects who were randomly 
selected from the same birth year and regions as the cases (Reefhuis et al. 2015; Kummet et 
al. 2016; Kutbi 2017). Subject enrollment and data collection in each study were approved 
by the appropriate institutional review boards. Descriptions of these studies and genotyping 
methods are in the online Appendix.
In the main analysis, we limited our sample to children born with isolated oral clefts 
(excluding cases with syndromes or other major birth defects). Because of differences in 
minor allele frequencies and possibly genetic effects by ancestry, we limited the sample 
from the US studies to self-reported non-Hispanic whites. Most participants in the Norway 
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studies were Caucasians (studies required eligible participants to be native speakers of 
Norwegian). In additional analyses, we examined effects of SNPs significantly related to 
isolated clefts on risk of nonisolated clefts.
The total analytic sample included 1,875 cases with isolated clefts, including 1,311 mother-
child dyads with genetic data on both mothers and children. The sample included 459 cases 
with nonisolated clefts, of whom 267 had mother-child dyad data, and 3,749 controls, 
including 2,481 mother-child dyads with genetic data. Appendix Table 2 shows the sample 
distribution by case-control group, cleft type, and genetic data availability for each study.
Statistical Analysis
Analyses were performed with the HAPLIN R package version 3.5. HAPLIN is based on a 
full maximum-likelihood approach and can estimate a variety of genetic parameters for case-
triad, case-dyad, case-control, and hybrid designs (Weinberg and Umbach 2005; Gjessing 
and Lie 2006; Skare et al. 2012). Because we had DNA on children and mothers for the 
majority of our sample, our estimation was primarily based on a hybrid case-control dyad 
design, in which fathers’ genotypes were probabilistically inferred from the child-mother 
dyad data. This design allows for estimating the most relevant genetic parameters. We 
included the genetic data of the smaller proportion of the sample with DNA only on mothers 
or children (Appendix Table 2) to optimize statistical power. Appendix Figure 1 shows that 
we had good power for testing fetal SNP effects even for moderate effect sizes and the 
power gain based on the total sample versus complete mother-child dyads. When mother-
only data were included, a probability distribution for possible child genotypes for a given 
SNP is estimated for each mother and used in deriving the fetal SNP effect. To ensure that 
our main estimates combining data from complete dyads with mother-only and child-only 
data are not biased, we performed sensitivity analyses that included only mother-child dyad 
data. Results from these analyses were virtually the same as those based on the full sample.
Our hybrid design allowed for complete separation of direct effects of maternal and fetal 
genes (Gjessing and Lie 2006; Buyske 2008) and estimation of PoO effects for fetal genes 
(Shi et al. 2012). All analyses were stratified by study to account for differences in allelic 
frequency and loci effects across studies and then combined in a meta-analysis after testing 
for effect heterogeneity between sites.
Our analysis proceeded through the following steps. Focusing first on cases with isolated 
OFC, we performed a screening analysis of each SNP using a model with a multiplicative 
dose-response effect of fetal alleles for each of the 3 case groups and Bonferroni adjustment 
for 31 SNPs (P < 0.0016). Our subsequent analyses for fetal effects focused on SNPs that 
had significant effects after our initial screening. For each SNP, we then estimated 
associations with each OFC case group for the single dose (heterozygotes) and double dose 
(homozygotes) of the minor allele. Next, we examined MG effects for each SNP controlling 
for the fetal genotype. Furthermore, we evaluated PoO effects by estimating the effect of a 
single dose of a minor allele inherited from the mother and that inherited from the father and 
tested the difference between these effects in heterozygotes. Finally, we estimated the fetal 
effects of SNPs with significant effects on isolated OFC from the first screen on non-isolated 
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OFC, combining nonisolated CLO and CLP (because of the smaller sample size of 
nonisolated cases).
Results
Fetal Allele Effects on Isolated OFC
Of the 31 fetal SNPs in the 17 examined loci, 14 SNPs in 12 loci had significant associations 
with isolated CLO or CLP or both after Bonferroni adjustment (Tables 1 and 2). SNPs 
within PAX7, IRF6, 8q21.3, 8q24, VAX1, KIAA1598, and MAFB had significant 
associations with both CLO and CLP. SNPs near TPM1 and NOG1 had significant 
associations only with CLO after Bonferroni adjustment, although these were weakly 
associated with CLP at nominal significance levels (P = 0.005 and 0.03, respectively). In 
contrast, SNPs at ABCA4-ARHGAP29, THADA, FOXE1, and SPRY2 had significant 
associations with CLP only. FOXE1 and SPRY2 SNPs were associated with CLO at nominal 
significant levels (P ≤ 0.01), but there was no evidence for associations of ABCA4-
ARHGAP29 or THADA with CLO. We did not observe significant associations at the other 
5 loci for either CLO or CLP, including MSX1, FGFR2, CRISPLD2, NTN1, and MYH9. 
There was little evidence of an association with these loci even at nominal significance 
levels (only NTN1 was weakly associated with CLO and CLP at P ≤ 0.05). The sensitivity 
analyses excluding mother-only and child-only genetic data showed similar results, with an 
overall slight decline in significance as expected; however, the relative risk estimates were 
very close, indicating no bias when these data were combined with mother-child dyad data 
(Appendix Tables 3 and 4).
Of all the examined loci, only the SNP at NOG1 had a significant association with isolated 
CPO (Table 3) in the opposite direction (minor allele protective) from that with CLO (or 
CLP). All other SNPs had insignificant associations even at P < 0.05, and most P values 
were large, ruling out any role for these loci in isolated CPO.
For all examined SNPs, there was no evidence of heterogeneity in effects across the pooled 
studies for each cleft type (Tables 1–3). The hypothesis of homogenous effects across 
studies could not be rejected, even at nominal significance levels for most SNPs, which 
supports the pooled results from stratified estimation across studies.
Dosage Effects of Fetal Alleles on Isolated OFC
Figure 1 shows the associations of single and double doses of minor fetal alleles for the 
SNPs that had significant associations with any cleft type. The overall patterns of 
associations were remarkably similar between isolated CLO and CLP, suggesting that CLO 
and CLP share similar etiology across most examined loci. Dose-response associations were 
consistent for most SNPs. For both CLO and CLP, the double doses of PAX7, 8q24, 8q21.3, 
KIAA1598-VAX1, SPRY2, TPM1, NOG1, and MAFB had larger associations than those for 
the single-dose alleles. This indicates that the simpler multiplicative model for the screening 
analyses fit the data well, with the advantage of estimating fewer parameters.
The largest association among all the loci was for SNP rs987525 of 8q24; the risk for both 
CLO and CLP increased 4-fold with the double dose, compared with a 2-fold increase for 
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the single dose. The next-largest positive associations for CLO risk were nearly 2-fold 
increased risks with the double minor allele doses of PAX7, IRF6, 8q21.3, KIAA1598-
VAX1, TPM1, and NOG1. For CLP, the next-largest positive associations were nearly 2-fold 
higher for the double minor allele doses of PAX7 and KIAA1598-VAX1, followed by 
smaller associations for ABCA4-ARHGAP29, IRF6, and 8q21.3. A few negative 
associations were also observed. The double minor allele dose of MAFB rs13041247 was 
associated with 50% reduction in risk of CLO or CLP. Similarly, the double minor allele 
dose of FOXE1 rs3758249 was associated with 25% reduction in CLO risk and 50% 
reduction in CLP risk, while the double minor allele dose of SPRY2 rs8001641 was 
associated with 30% reduction in risk of CLO or CLP. Appendix Table 5 reports the 
estimates for risks associated with the major alleles of these 3 loci (MAFB, FOXE1, and 
SPRY2) when the minor allele is used as reference.
A very different pattern was observed for isolated CPO, with most single and double minor 
allele dose effects being close to the null and nonsignificant. Only NOG1 rs227731 had 
significant single- and double-dose associations with 50% reduction in risk with the double-
dose effect.
MG Effects
We observed no evidence of MG effects after adjusting for multiple comparisons, and most 
effects were close to the null (Appendix Tables 6–8). It is worth noting, however, that IRF6 
rs2235371 (P = 0.02) and CRISPLD2 rs1546124 (P = 0.003) were significant without such 
adjustment for isolated CLP (Appendix Table 7) and that FOXE1 rs74934500 (P = 0.02), 
KIAA1598-VAX1 rs4752028 (P = 0.03), and FGFR2 rs3750817 (P = 0.01) were significant 
for isolated CPO without adjustment (Appendix Table 8).
PoO Effects
There was no evidence of PoO effects, and most associations were similar between maternal 
and paternal alleles (Appendix Tables 9 and 10). However, 8q21.3 had a marginally 
significant larger effect on isolated CLO risk when originating from the mother (relative risk 
= 1.54 vs. 1.08, P value of difference = 0.06), while 8q24 had a marginally significant larger 
effect on isolated CLP risk when originating from the father (relative risk = 2.11 vs. 1.66, P 
value of difference = 0.08). We examined PoO effects for the 14 SNPs for isolated CPO for 
comparison and observed no significant PoO differences, including for NOG1 (Appendix 
Table 11). There was, however, increased risk with paternal allele of KIAA1598-VAX1 but 
reduced risk with maternal allele (P value of difference = 0.06).
Fetal Effects on Isolated versus Nonisolated OFC
Since we found associations that were generally similar for isolated CLO and CLP, we 
performed an analysis combining these 2 groups of cases to examine whether associations 
for isolated CL/P were different from those of nonisolated CL/P (Fig. 2). Overall, the 
associations with most loci had similar directions and close magnitudes between isolated 
and nonisolated CL/P, although many effects for the smaller sample of nonisolated CL/P 
were nonsignificant. However, the associations with the single and double minor allele doses 
of 8q24, the single allele dose of KIAA1598-VAX1, and double allele doses of PAX7, 
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THADA, TPM1, and NOG1 on nonisolated CL/P were significant at nominal levels (P < 
0.05). Overall, these results indicate that these loci play a similar role in both isolated and 
nonisolated CL/P.
We performed a similar analysis comparing isolated CPO with nonisolated CPO. The only 
SNP with a significant association for isolated CPO (NOG1 rs227731) had similar risks for 
nonisolated CPO (Appendix Fig. 3). The double minor allele for PAX7 was associated with 
a significant increase in nonisolated but not isolated CPO risk. No other significant 
associations were observed for nonisolated CPO.
Discussion
Using the largest sample to date of individuals of European descent, we investigated 31 
SNPs within 17 top loci for OFC from previous GWASs and candidate gene studies. Our 
initial screening of fetal alleles with Bonferroni adjustment for isolated CLO, CLP, and CPO 
found significant associations for 14 SNPs in 12 loci; most associations were consistent with 
a dose-response allelic effect. Most SNPs had remarkably similar effects between isolated 
CLO and CLP. Potential exceptions were ABCA4-ARHGAP29 and THADA, which were 
significantly associated with isolated CLP but not CLO. In contrast, TPM1 and NOG1 had 
stronger associations with isolated CLO than CLP. There was no evidence of significant 
associations with isolated CPO except for NOG1 (rs227731), which had opposite effects on 
CPO and CLO—reduction (increase) in CPO (CLO) risk with the minor allele. Our study is 
the first to report differential effects of ABCA4-ARHGAP29 on CLP and CLO and opposite 
NOG1 effects on CLO and CPO, including the significant reduction in CPO risk. The lack 
of significant associations of other loci with isolated CPO is consistent with prior studies 
(Beaty et al. 2011; Böhmer et al. 2013; Leslie et al. 2017; Ludwig et al. 2017) and studies of 
familial recurrence suggesting a distinct etiology for CPO in many, if not most, cases 
(Sivertsen et al. 2008; Grosen et al. 2010). Among all examined loci, 8q24 (rs987525) had 
the strongest effects on isolated CLO and CLP. There was little evidence of prominent MG 
or PoO effects consistent with previous studies (Shi et al. 2012; Garg et al. 2014) and 
findings of similar mother-offspring and father-offspring OFC recurrences (Sivertsen et al. 
2008; Grosen et al. 2010), suggesting that such effects do not play a major role in the 
etiologic mechanisms of almost all the examined loci. A detailed discussion of key loci 
findings is in the online Appendix. We did not find significant associations for CLO or CLP 
with MSX1, FGFR2, CRISPLD2, NTN1, and MYH9, suggesting that prior findings for 
these loci are perhaps not generalizable to population-based samples and are possibly more 
specific to selective clinic-based samples.
Our comparison of locus effects between isolated and non-isolated CL/P revealed 
remarkable similarity in direction and magnitude between the 2 cleft groups for most loci. 
The strongest evidence was observed for 8q24 (rs987525), which had similar significant 
effects (at P < 0.05) on nonisolated CL/P in both single and double minor allele doses, 
despite the much smaller sample size. Other loci had significant associations (at P < 0.05) in 
double minor allele forms (PAX7, THADA, TPM1, and NOG) or single minor allele dose 
(KIAA1598-VAX1). This finding suggests that these loci are modifiers of cleft risk in both 
isolated and nonisolated forms and that combining isolated and nonisolated CLO and CLP 
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may be considered in initial GWAS analyses to increase power for identifying such variants. 
Such analyses would complement analyses specific to isolated forms. Furthermore, it 
indicates that genetic pathways and possibly even the same etiologic variants converge to 
contribute risk for CL/P under syndromic and nonsyndromic genetic backgrounds. This 
reduction in heterogeneity facilitates the design of studies to disentangle the contribution of 
such variants to OFC etiology. However, it is possible that loci effects on OFC risk within 
the nonisolated group may vary by etiology of the noncleft malformations, for example, 
between cases with known syndromes and those of unknown etiologies. Examining this 
potential heterogeneity in future work is important for understanding the contribution of 
these loci to nonisolated OFC risk. In conclusion, this study represents the largest 
population-based examination of top loci suggested for isolated OFC to date. We provide 
further evidence of the notion of different genetic etiologies between isolated CL/P and CPO 
and similar genetic etiologies between CLO and CLP for most top loci identified to date. 
The similarity in effects of most loci between CLO and CLP supports pooling these 
phenotypes in preliminary GWAS analyses to maximize power. We provide novel evidence 
of remarkable similarity in effects of top loci between isolated and nonisolated forms of 
CL/P, suggesting that nonisolated forms may be included in initial GWAS analyses to 
maximize power and that studying syndromic forms can continue to inform our 
understanding of molecular mechanisms underlying the nonsyndromic forms. We 
consistently observed dose-response allelic effects for most loci, allowing for more accurate 
estimation of genetic effects and providing additional evidence on the likelihood that the 
effects have a biological basis.
The strengths of our study include a pooled analysis of individual-level data from large 
population-based samples allowing for precise estimation of loci effects on risk and reducing 
ascertainment bias. One potential caveat is incomplete accounting for population 
stratification since we do not have GWAS data to fully capture ancestry. However, this is 
unlikely to meaningfully affect our results since the majority of our sample is of Caucasian 
ancestry. While it is possible that some variants may vary in allelic distribution or risk 
associations across different ancestries among self-reported whites, we did not find 
significant heterogeneity in association across the 5 study populations we examined. 
Furthermore, some of the dyad-case samples with isolated OFC from the Utah and Norway 
studies were included in a previous GWAS (Beaty et al. 2010). However, these cases were 
previously analyzed with a model of allelic transmission within triads with OFC and not 
with the combined dyad and case-control design as we did here. Therefore, there is little 
overlap with previous work that included these samples.
Our results can be considered the most reliable estimates to date of the effects of these top 
loci on risks of isolated OFC in a population of European descent. These estimates can be 
used to generate polygenic risk scores to predict risks of CLO or CLP in other smaller data 
sets with data on the top significant SNPs. Furthermore, they may be informative for 
predicting risk of oral clefts in cases for whom screening is being considered such as 
individuals with a family history of clefts. Our analysis focused on the effects of each SNP 
on its own. Obviously, individuals can have combinations of risk alleles across these SNPs 
that are associated with different cleft risks, and investigating these combinations in future 
studies is meaningful to better understand and quantify risk heterogeneity. Also, estimating 
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the effects of causal variants (not only GWAS lead SNPs) and new loci as they are identified, 
such as GRHL3 for CPO (Leslie, Liu, et al. 2016), is needed for more accurate risk 
prediction.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Single- and double-dose effects measured by relative risks (RRs) for minor alleles of the 15 
fetal single-nucleotide polymorphisms that had significant effects for 1 of the case 
categories: isolated cleft lip only (CLO), isolated cleft lip and palate (CLP), and isolated 
cleft palate only (CPO). Black squares represent single-dose effects; red squares represent 
double-dose effects; and lines are 95% confidence intervals. We include only rs3758249 in 
FOXE1 in this figure because haplotype analysis indicated that the effect of rs10984103 is 
explained by the minor allele of the first single-nucleotide polymorphism (Appendix Fig. 2).
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Figure 2. 
Single- and double-dose effects measured by relative risks (RRs) for minor alleles of 15 fetal 
single-nucleotide polymorphisms for the poled category of isolated cleft lip only (CLO) or 
isolated cleft lip and palate (CLP; first panel) and for nonisolated cleft lip only or 
nonisolated cleft lip and palate (second panel). Black squares represent single-dose effects; 
red squares represent double-dose effects; and lines are 95% confidence intervals.
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